A Genetic Model for Colorectal Tumorigenesis Review

Total Page:16

File Type:pdf, Size:1020Kb

A Genetic Model for Colorectal Tumorigenesis Review Cell, Vol. 61, 759-767, June 1, 1990, Copyright 0 1990 by Cell Press A Genetic Model Review for Colorectal Tumorigenesis Eric Ft. Fearon and Bert Vogelstein having arisen from numerous stem cells. Thus, adenomas The Oncology Center arise from a single pocket of epithelial stem cells (Ponder Program in Human Genetics and Wilkinson, 1988) consistent with the idea that one or The Johns Hopkins University School of Medicine a small number of cells from within this pocket initiate the Baltimore, Maryland 21231 process of neoplasia by clonal expansion. In an attempt to gain an understanding of the molecular basis for this clonal expansion, investigators have sought Tumorigenesis has long been thought to be a multistep to identify somatic alterations present at various stages of process (Foulds, 1958); however, only recently has it be- colorectal tumor formation. Of particular interest are alter- come possible to identify the molecular events that under- ations present in all or virtually all of the neoplastic cells lie the initiation and progression of human tumors (Wein- studied. The presence of such an alteration suggests that berg, 1989; Bishop, 1987). Colorectal tumors provide an the genetic alteration itself provided the cell with a growth excellent system in which to search for and study the advantage, allowing it to outgrow other neoplastic cells genetic alterations involved in the development of a com- within the tumor to become the predominant cell type con- mon human neoplasm. Abundant clinical and histopatho- stituting the neoplasm (clonal expansion). Alternatively, logical data suggest that most, if not all, malignant colo- the genetic alteration, even if present in every neoplastic rectal tumors (carcinomas) arise from preexisting benign cell of an individual tumor, could have arisen coinciden- tumors (adenomas) (Sugarbaker et al., 1985). Tumors of tally with another change that actually provided the selec- various stages of development, from very small adeno- tive growth advantage. When the same genetic alteration mas to large metastatic carcinomas, can be obtained for is observed in many different tumors, the former explana- study, unlike the situation in most other common human tion is more likely. tumor types. Furthermore, both hereditary and environ- mental factors contribute to the development of colorectal Genetic Alterations in Oncogenes neoplasia, allowing for the study of both inherited and so- One important type of somatic alteration identified in matic genetic alterations. colorectal tumors is ras gene mutation. When transfected In this review we present a model for the genetic basis into appropriate recipient cells, mutated ras genes confer of colorectal neoplasia that includes the following salient neoplastic properties (reviewed in Barbacid, 1987; Wein- features. First, colorectal tumors appear to arise as a re- berg, 1989). Approximately 50% of colorectal carcinomas sult of the mutational activation of oncogenes coupled (Bos et al., 1987; Forrester et al., 1987) and a similar per- with the mutational inactivation of tumor suppressor genes; centage of adenomas greater than 1 cm in size have been the latter changes predominate. Second, mutations in at found to have ras gene mutations (Vogelstein et al., 1988). least four to five genes are required for the formation of In contrast, such mutations have been identified in fewer a malignant tumor. Fewer changes suffice for benign than 10% of adenomas less than 1 cm in size (Figure l), tumorigenesis. Third, although the genetic alterations of- regardless of whether the adenomas arose sporadically ten occur according to a preferred sequence, the total ac- or in patients with an inherited predisposition for their for- cumulation of changes, rather than their order with re- mation (Vogelstein et al., 1988; Farr et al., 1988). ras gene spect to one another, is responsible for determining the mutations may be the initiating event in a subset of co- tumor’s biologic properties. Fourth, in some cases, mutant lorectal tumors, and adenomas with ras gene mutations tumor suppressor genes appear to exert a phenotypic ef- may be more likely to progress than adenomas without fas fect even when present in the heterozygous state; thus, gene mutations. Alternatively, fas gene mutations may not some tumor suppressor genes may not be “recessive” at be the initiating event in most tumors, usually occurring the cellular level. The general features of this model may only in one cell of a preexisting adenoma. Such mutations be applicable to other common epithelial neoplasms, in would then be responsible for the conversion of a small which tumors of varying stage are more difficult to study. adenoma to a larger and more dysplastic one, through clonal expansion of the cell with the mutation. The Clonal Nature of Colonic Neoplasia In addition to somatic activation by point mutation, on- Various hypotheses for the development of cancer have cogenes may be activated by amplification or rearrange- been proposed. Mutational theories predict that neo- ment. Although the existence of amplified genes in a sig- plasms will have a monoclonal composition, whereas nificant percentage of colorectal tumors was suggested by aberrant differentiation processes or field effects might be the presence of double-minute chromosomes or homo- predicted to give rise to neoplasms with a polycolonal geneously stained regions in karyotypic analyses (Reich- composition. Although the earliest events in human co- mann et al., 1981) few cases of specific gene amplifica- lorectal tumor formation are not yet defined, study of the tion have been reported. These cases include examples clonal composition of human colorectal tumors has dem- of neu, c-myc, or c-myb amplification in primary colorectal onstrated that all tumors examined, including very small tumors or their derived cell lines (D’Emilia et al., 1989; adenomas, have a monoclonal composition (Fearon et al., Alitalo et al., 1983, 1984; Finley et al., 1989). In addition, 1987). In contrast, normal colonic epithelium is polyclonal, oncogene rearrangements, other than a single case of Cell 760 1987; Leppert et al., 1987). In patients without polyposis, allelic losses of chromosome 5q have been observed in 20%~50% of colorectal carcinomas and in about 30% of colorectal adenomas (Vogelstein et al., 1988; Sasaki et al., 1989). However, in adenomas from patients with familial adenomatous polyposis, allelic losses of chromosome 5q are rare (Solomon et al., 1987; Vogelstein et al., 1988; Sasaki et al., 1989). Thus, although each adenoma in a patient with polyposis appears to arise by clonal expan- sion (Fearon et al., 1987) this expansion is not associated EMILY INTERMEDIATE LATE CARCINOMA with allelic losses of the loci flanking the region linked to ADENOMA ADENOMA ADENOMA the disease. This finding contrasts with the pattern of al- TYPE OF TUMOR lelic loss seen in other inherited tumor predisposition syn- Figure 1. Frequency of ras Gene Mutations and Chromosome 17~ De- dromes; the implications of this finding will be discussed letions in Colorectal Tumors below. Early-stage adenomas were defined as adenomas that were 1.0 cm in The loss of a large portion of chromosome 17p, through size or less. Intermediate stage adenomas were greater than 1.0 cm chromosome loss or mitotic recombination, has been in size and did not contain foci of carcinoma. Late-stage adenomas seen in more than 75% of colorectal carcinomas (Vogel- were greater than 1.0 cm in size and contained foci of carcinoma (the stein et al., 1988; Delattre et al., 1989) but such loss is rel- adenomatous elements were separated from the nonadenomatous elements before analysis). DNA was prepared from all specimens by atively infrequent in adenomas of any stage (Figure 1). a cyrostat sectioning technique to enrich for areas of tumor that com- Moreover, in several patients the 17p allelic losses were prised 70% or greater neoplastic cells. ras gene mutations were identi- found to be associated with the progression of individual fied by oligonucleotide hybridization to DNA samples in which ras tumors from adenoma to carcinoma (Fearon et al., 1987; gene-specific sequences had been amplified by the polymerase chain reaction. Chromosome 17p losses were detected by study of DNA from Vogelstein et al., 1988). Other common adult tumors, in- normal colorectal mucosa and tumor tissue with probes detecting DNA cluding those of the breast (Mackay et al., 1988; Devilee polymorphisms on chromosome 17 (Vogelstein et al., 1966). et al., 1989) lung (Yokotaet al., 1987; Weston et al., 1989), bladder (Tsai et al., 1990) and brain (James et al., 1989), also have been found to have frequent losses of chromo- rearrangement of the frk oncogene (Martin-Zanca et al., some 17p alleles. The common region of loss on chromo- 1986) have not been observed in colorectal tumors. Thus, some 17p in colorectal tumors has been identified and the evidence to date does not support a major role for am- contains the ~53 gene (Baker et al., 1989). Furthermore, plification or rearrangement of oncogenes in the genesis mutations resulting in amino acid substitutions in the ~53 of colorectal neoplasms. gene product have been observed in the remaining ~53 alleles of several colorectal cancers that had concomitant Allelic Losses and Tumor Suppressor Genes allelic losses of chromosome 17p (Baker et al., 1989; Nigro A loss of specific chromosomal regions occurs frequently et al., 1989). Thus, point mutation of one allele of the ~53 in colorectal neoplasia. Usually the losses involve only gene coupled with loss of the remaining wild-type allele one of the two parental chromosomes present in normal appears to occur frequently in colorectal tumors. Similar cells. These allelic losses have been interpreted as evi- mutations have been observed in the remaining ~53 al- dence that the regions affected contain tumor suppressor leles of lung, breast, and brain tumors with chromosome genes, whose products normally regulate growth and dif- 17p losses (Nigro et al., 1989; Takahashi et al., 1989; lggo ferentiation in a negative fashion and thus indirectly sup- et al., 1990).
Recommended publications
  • Medical Advisory Board September 1, 2006–August 31, 2007
    hoWard hughes medical iNstitute 2007 annual report What’s Next h o W ard hughes medical i 4000 oNes Bridge road chevy chase, marylaNd 20815-6789 www.hhmi.org N stitute 2007 a nn ual report What’s Next Letter from the president 2 The primary purpose and objective of the conversation: wiLLiam r. Lummis 6 Howard Hughes Medical Institute shall be the promotion of human knowledge within the CREDITS thiNkiNg field of the basic sciences (principally the field of like medical research and education) and the a scieNtist 8 effective application thereof for the benefit of mankind. Page 1 Page 25 Page 43 Page 50 seeiNg Illustration by Riccardo Vecchio Südhof: Paul Fetters; Fuchs: Janelia Farm lab: © Photography Neurotoxin (Brunger & Chapman): Page 3 Matthew Septimus; SCNT images: by Brad Feinknopf; First level of Rongsheng Jin and Axel Brunger; iN Bruce Weller Blake Porch and Chris Vargas/HHMI lab building: © Photography by Shadlen: Paul Fetters; Mouse Page 6 Page 26 Brad Feinknopf (Tsai): Li-Huei Tsai; Zoghbi: Agapito NeW Illustration by Riccardo Vecchio Arabidopsis: Laboratory of Joanne Page 44 Sanchez/Baylor College 14 Page 8 Chory; Chory: Courtesy of Salk Janelia Farm guest housing: © Jeff Page 51 Ways Illustration by Riccardo Vecchio Institute Goldberg/Esto; Dudman: Matthew Szostak: Mark Wilson; Evans: Fred Page 10 Page 27 Septimus; Lee: Oliver Wien; Greaves/PR Newswire, © HHMI; Mello: Erika Larsen; Hannon: Zack Rosenthal: Paul Fetters; Students: Leonardo: Paul Fetters; Riddiford: Steitz: Harold Shapiro; Lefkowitz: capacity Seckler/AP, © HHMI; Lowe: Zack Paul Fetters; Map: Reprinted by Paul Fetters; Truman: Paul Fetters Stewart Waller/PR Newswire, Seckler/AP, © HHMI permission from Macmillan Page 46 © HHMI for Page 12 Publishers, Ltd.: Nature vol.
    [Show full text]
  • GSA Welcomes 2012 Board Members
    7INTERs3PRING 4HE'3!2EPORTER winter s spring 2012 New Executive GSA Welcomes 2012 Board Members Director Now on Board The Genetics Society of America New Members of the GSA Board of welcomes four new members elected Directors Adam P. Fagen, by the general membership to the Ph.D., stepped in as 2012 GSA Board of Directors. The VICE PRESIDENT: GSA’s new Executive new members are: Michael Lynch Michael Lynch, Director beginning (Indiana University), who serves as Distinguished December 1, 2011. vice president in 2012 and as GSA Professor of Dr. Fagen previously president in 2013 and Marnie E. Biology, Class of was at the American Halpern (Carnegie Institution for 1954 Professor, Society of Plant Science); Mohamed Noor (Duke Department of Biologists (ASPB), University); and John Schimenti Biology, Indiana where he was the director of public (Cornell University), who will serve as University, continued on page nineteen directors. Bloomington. Dr. Lynch is a population and evolutionary biologist and a In addition to these elected officers, long-time member of GSA. Dr. Lynch 2012 Brenda J. Andrews (University of sees GSA as the home for geneticists Toronto), Editor-in-Chief of GSA’s who study a broad base of topics GSA Award journal, G3: Genes|Genomes|Genetics, and organisms, and as a forum Recipients which was first published online in where general discussion occurs, June 2011, becomes a member of the whether based on the principles Announced Board of Directors. The bylaws have of genetics, the most pressing historically included the GENETICS GSA is pleased to announce the issues within the discipline itself, or editor-in-chief on the Board and as a responses to societal concerns and/ 2012 recipients of its five awards result of a 2011 bylaw revision, the G3 for distinguished service in the or conflicts within applied genetics.
    [Show full text]
  • Humankind 2.0: the Technologies of the Future 6. Biotech
    Humankind 2.0: The Technologies of the Future 6. Biotech Piero Scaruffi, 2017 See http://www.scaruffi.com/singular/human20.html for the full text of this discussion A brief History of Biotech 1953: Discovery of the structure of the DNA 2 A brief History of Biotech 1969: Jon Beckwith isolates a gene 1973: Stanley Cohen and Herbert Boyer create the first recombinant DNA organism 1974: Waclaw Szybalski coins the term "synthetic biology” 1975: Paul Berg organizes the Asilomar conference on recombinant DNA 3 A brief History of Biotech 1976: Genentech is founded 1977: Fred Sanger invents a method for rapid DNA sequencing and publishes the first full DNA genome of a living being Janet Rossant creates a chimera combining two mice species 1980: Genentech’s IPO, first biotech IPO 4 A brief History of Biotech 1982: The first biotech drug, Humulin, is approved for sale (Eli Lilly + Genentech) 1983: Kary Mullis invents the polymerase chain reaction (PCR) for copying genes 1986: Leroy Hood invents a way to automate gene sequencing 1986: Mario Capecchi performs gene editing on a mouse 1990: William French Anderson’s gene therapy 1990: First baby born via PGD (Alan Handyside’s lab) 5 A brief History of Biotech 1994: FlavrSavr Tomato 1994: Maria Jasin’s homing endonucleases for genome editing 1996: Srinivasan Chandrasegaran’s ZFN method for genome editing 1996: Ian Wilmut clones the first mammal, the sheep Dolly 1997: Dennis Lo detects fetal DNA in the mother’s blood 2000: George Davey Smith introduces Mendelian randomization 6 A brief History of Biotech
    [Show full text]
  • Evolutionarily Conserved Protein ERH Controls CENP-E Mrna Splicing and Is Required for the Survival of KRAS Mutant Cancer Cells
    Evolutionarily conserved protein ERH controls CENP-E PNAS PLUS mRNA splicing and is required for the survival of KRAS mutant cancer cells Meng-Tzu Wenga,b,c, Jih-Hsiang Leea, Shu-Chen Weid, Qiuning Lia, Sina Shahamatdara, Dennis Hsua, Aaron J. Schettere, Stephen Swatkoskif, Poonam Mannang, Susan Garfieldg, Marjan Gucekf, Marianne K. H. Kima, Christina M. Annunziataa, Chad J. Creightonh, Michael J. Emanuelei, Curtis C. Harrise, Jin-Chuan Sheud, Giuseppe Giacconea, and Ji Luoa,1 aMedical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; bGraduate Institute of Clinical Medicine, National Taiwan University, Taipei 100, Taiwan; cFar-Eastern Memorial Hospital, Taipei 220, Taiwan; dDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei 100, Taiwan; eLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; fProteomics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892; gConfocal Microscopy Core Facility, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; hDepartment of Medicine and Dan L. Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX 77030; and iDepartment of Genetics, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA 02115 Edited by Bert Vogelstein, Johns Hopkins University, Baltimore, MD, and approved November 12, 2012 (received for review June 1, 2012) Cancers with Ras mutations represent a major therapeutic prob- anaphase-promoting complex (APC/C) that coordinately maintain lem. Recent RNAi screens have uncovered multiple nononcogene the fidelity of chromosome segregation (6). Symmetrical distribu- addiction pathways that are necessary for the survival of Ras mu- tion of chromosomes during mitosis is critical for genomic stability tant cells.
    [Show full text]
  • Facultad De Ciencias Universidad Autónoma De San Luis Potosí
    Boletín de La Ciencia en San Luis Facultad de Ciencias Universidad Autónoma de San Luis Potosí No.1, 8 de junio de 1998 Presentación Boletín de información científica y El noticiero radiofónico La Ciencia en tecnológica de la Facultad de Ciencias San Luis que recientemente celebró su quinto aniversario, ha cumplido un ciclo. Publicación semanal A partir de esta fecha dejará de transmitirse por Radio Universidad; sin embargo, para continuar su labor de Edición y textos difusión el contenido del noticiero Fís. J. Refugio Martínez Mendoza aparecerá en forma de boletín. Además para recalcar su dependencia de la Facultad de Ciencias se incluirá una Cualquier información, artículo o sección que trata sobre las noticias e anuncio deberá enviarse al editor informaciones académicas de la e-mail: [email protected] Facultad, con lo cual se pretende sirva Este boletín puede consultarse por como un enlace y un medio de Internet en la página de la UASLP comunicación interna. Agradecemos las facilidades que se le den a este Boletín, así como cualquier colaboración que la · Einstein sigue dando de que hablar comunidad de la Facultad de Ciencias y de la Universidad quiera realizar. · Ahora la oveja clonada es madre Ponemos a disposición de los estudiantes de la Facultad este medio para cualquier · Argenina, un nutriente importante opinión o inquietud académica que tengan que comunicar, con respecto al · Más sobre terapias para tratar el desarrollo de nuestra Facultad y de SIDA nuestra Universidad. En principio, siempre y cuando se respeten las formas · Dinosaurios y aves de relación respetuosa, no habrá censura; por lo que se pueden expresar opiniones y críticas “positivas”.
    [Show full text]
  • Activity 1 and 2 Overview
    2013 Holiday Lectures on Science OVERVIEW OF CANCER DISCOVERY ACTIVITIES Medicine in the Genomic Era EDUCATOR MATERIALS OVERVIEW OF CANCER DISCOVERY ACTIVITIES This educator guide provides support for two Cancer Discovery activities, both based on a Howard Hughes Medical Institute 2013 Holiday Lectures on Science video featuring researcher Dr. Charles L. Sawyers. Students begin by watching the online video clip, Cancer as a Genetic Disease (http://www.hhmi.org/biointeractive/ cancer-genetic-disease-video-highlights), and completing the accompanying Video Worksheet. After that assignment, instructors can decide which of the two activities to use in class. Activity 1: Classifying Cancer Genes In Activity 1, students identify the locations on chromosomes of genes involved in cancer, or “cancer genes.” Using the set of 139 Cancer Gene Cards and associated chromosome posters, students discover the following: • About 140 human genes are currently known to be involved in cancer. • Cancer genes are located throughout the human genome. • The proportion of oncogenes versus tumor suppressor genes is roughly equal. • The main cellular processes affected by mutations in cancer genes are cell survival, cell fate, and genome maintenance. • One way to visualize genetic data is to map genes onto chromosomes. Activity 2: Examining Cancer Patient Data In Activity 2, students explore the genetic basis of cancer by examining cards that list genetic mutations found in the DNA of actual cancer patients. Small-group work spurs discussion about the genes that are mutated in different types of cancers and the cellular processes that the affected genes control. Students are asked to identify patterns and trends in the data.
    [Show full text]
  • Michel Foucault Ronald C Kessler Graham Colditz Sigmund Freud
    ANK RESEARCHER ORGANIZATION H INDEX CITATIONS 1 Michel Foucault Collège de France 296 1026230 2 Ronald C Kessler Harvard University 289 392494 3 Graham Colditz Washington University in St Louis 288 316548 4 Sigmund Freud University of Vienna 284 552109 Brigham and Women's Hospital 5 284 332728 JoAnn E Manson Harvard Medical School 6 Shizuo Akira Osaka University 276 362588 Centre de Sociologie Européenne; 7 274 771039 Pierre Bourdieu Collège de France Massachusetts Institute of Technology 8 273 308874 Robert Langer MIT 9 Eric Lander Broad Institute Harvard MIT 272 454569 10 Bert Vogelstein Johns Hopkins University 270 410260 Brigham and Women's Hospital 11 267 363862 Eugene Braunwald Harvard Medical School Ecole Polytechnique Fédérale de 12 264 364838 Michael Graetzel Lausanne 13 Frank B Hu Harvard University 256 307111 14 Yi Hwa Liu Yale University 255 332019 15 M A Caligiuri City of Hope National Medical Center 253 345173 16 Gordon Guyatt McMaster University 252 284725 17 Salim Yusuf McMaster University 250 357419 18 Michael Karin University of California San Diego 250 273000 Yale University; Howard Hughes 19 244 221895 Richard A Flavell Medical Institute 20 T W Robbins University of Cambridge 239 180615 21 Zhong Lin Wang Georgia Institute of Technology 238 234085 22 Martín Heidegger Universität Freiburg 234 335652 23 Paul M Ridker Harvard Medical School 234 318801 24 Daniel Levy National Institutes of Health NIH 232 286694 25 Guido Kroemer INSERM 231 240372 26 Steven A Rosenberg National Institutes of Health NIH 231 224154 Max Planck
    [Show full text]
  • AACI to Honor Pioneer in Breast Cancer Research, Precision Medicine
    Association of American Cancer Institutes For more information contact: Chris Zurawsky Association of American Cancer Institutes (412) 802-6775 [email protected] www.aaci-cancer.org May 2, 2018 AACI to Honor Pioneer in Breast Cancer Research, Precision Medicine Charles M. Perou, PhD, will receive the AACI Distinguished Scientist Award on October 1, during the 2018 AACI/CCAF Annual Meeting, in Chicago. Prior to the award presentation, Dr. Perou will deliver a talk focused on sequencing studies for gene expression analysis, specifically, on research results showing the value of sequencing-based approaches in breast and lung cancers. Dr. Perou is The May Goldman Shaw Distinguished Professor of Molecular Oncology, Professor of Genetics and of Pathology & Laboratory Medicine, at UNC Lineberger Comprehensive Cancer Center. His research interests span the disciplines of cancer biology, genomics, genetics, bioinformatics, statistics, systems biology, and the treatment of cancer patients in the clinic. AACI’s award recognizes Dr. Perou’s research accomplishments in the field of precision medicine and his groundbreaking research in the characterization of the diversity of human tumors. The clinical value of Dr. Perou’s work leading to the discovery of the “Intrinsic Subtypes of Breast Cancer” has had a profound impact on the treatment of patients with breast cancer worldwide. In addition, his lab has successfully created computational predictors of complex cancer phenotypes which will ultimately have clinical application. Dr. Perou has been a faculty member at UNC since 2000 and is the Faculty Director of UNC Lineberger’s Bioinformatics Group, and Co-Director of its Breast Cancer Research Program. He has authored more than 330 peer-reviewed articles, and am an inventor on five American and European patents.
    [Show full text]
  • We Thought, 'This Is a Way Our Lab
    Bert Vogelstein LUDWIG WORKING FROM HOME “We thought, ‘This is a way our lab can contribute right now.’ That’s what we should be focusing on.” 6 The cancer detector IN EARLY 2020, BERT VOGELSTEIN Though infectious disease is not quite watched with growing dread as the novel Vogelstein’s bailiwick, the proposed coronavirus infection (COVID-19) that intervention bore some similarity to his emerged from China swept across the team’s primary focus these days: secondary globe and infiltrated all 50 states of the cancer prevention—the application of U.S. By early April, COVID-19 had surpassed cancer genomics to catching cancers early, heart disease and cancer as the country’s before they spread and turn deadly. To that leading cause of death per day and brought end, the team he leads as Co-director of the nation’s economy to a standstill. But Ludwig Johns Hopkins has in recent years Vogelstein’s distress turned to resolve when designed and evaluated minimally invasive he realized that he and his team were in a tests (or “liquid biopsies”) to screen patients unique position to help. A drug they had for multiple undiagnosed malignancies. previously found might quell a dangerous In 2019, they reported the advantages of over-reaction of the immune response using one such test to screen colorectal known as a “cytokine storm” could potentially cancer patients for disease recurrence; In prevent the same condition in people with April this year, they published the results of severe COVID-19. the first clinical evaluation in the general population of a blood-based screening test “We thought,” says Vogelstein, “‘This is a way for multiple cancers.
    [Show full text]
  • Japan Prize 2021
    dic196 2021 SINCE 1985 www.japanprize.jp ARK Mori Building, East Wing 35th Floor, 1-12-32 Akasaka, Minato-ku, Tokyo, 107-6035, JAPAN Tel: +81-3-5545-0551 Fax: +81-3-5545-0554 CONTENTS Significance of the JAPAN PRIZE -2- JAPAN PRIZE - Peace and prosperity for mankind -3- The Japan Prize Foundation -4- Directors, Auditors and Councilors of the Foundation Main Activities of the Foundation -6- THE JAPAN PRIZE -8- Nomination and Selection Process Fields Selection Committee and Selection Committee Eligible Fields for the 2022 Japan Prize Profiles of Japan Prize Laureates -11- Donating to our Foundation -49- Significance of the JAPAN PRIZE Chairman Yoshio Yazaki The peace and prosperity of mankind are the common Konosuke Matsushita, and many of the predecessors aspirations for people of the world. When looking back over involved in the creation of the prize still live on in Matsushi- the history of humanity, science and technology have played ta’s philosophy of “Lifelong Ambition”. an immense role in this cause. Every year in April, the Presentation Ceremony and The Japan Prize is an international award presented to Banquet are held in Tokyo in the presence of Their Majesties individuals whose original and outstanding achievements the Emperor and Empress of Japan, and are also attended by are not only scientifically impressive but have also served to prominent figures such as the Speaker of the House of Repre- promote peace and prosperity for all mankind. Since its sentatives, the President of House of Councilors, the Chief inception in 1985, the Foundation has awarded 101 laureates Justice of the Supreme Court, as well as other distinguished from 13 countries as of this year.
    [Show full text]
  • The Paul Ehrlich Foundation
    The Paul Ehrlich Foundation Office of the Paul Ehrlich Foundation Contents Paul Ehrlich-Stiftung c/o Vereinigung von Freunden und Förderern der Goethe-Universität Theodor-W.-Adorno-Platz 1 Preface 5 60629 Frankfurt am Main E-Mail: [email protected] www.paul-ehrlich-stiftung.de Paul Ehrlich: His Life March 2021 and Achievements 6 Ludwig Darmstaedter: Donation account: Scientist and Friend 12 Deutsche Bank AG IBAN: DE38 5007 0010 0700 0839 00 BIC: DEUTDEFFXXX The Foundation, the Prize and the Role of Hedwig Ehrlich 14 The Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers 17 Preface In honor of the great German doctor and Paul Ehrlich, like all great researchers, was serologist who turned Frankfurt into a way ahead of his time. His research work medical eldorado at the beginning of the laid the cornerstone for the medical stand- 20th century, the Paul Ehrlich and Ludwig ards still valid today. In awarding the Paul Darmstaedter Prize is awarded to scientists Ehrlich and Ludwig Darmstaedter Prize, the from all over the world who have achieved Foundation wishes to encourage scientists all outstanding results in Paul Ehrlich’s field over the world to do what Paul Ehrlich did of work. throughout his entire life: extend medical know-how and make a contribution to the The prize given by the Paul Ehrlich constant struggle against illness and disease- Foundation is one of Germany’s most emi- induced mortality. nent accolades in recognition of outstand- ing achievements in biomedical research. The President of the German Research Foundation (DFG) is Honorary President of the Paul Ehrlich Foundation.
    [Show full text]
  • Nominations for Breakthrough Prizes in Life Sciences Now Open Online
    Nominations for Breakthrough Prizes in life sciences now open online 04 September 2013 | News | By BioSpectrum Bureau Nominations for Breakthrough Prizes in life sciences now open online The Breakthrough Prize in Life Sciences Foundation recently announced the opening of online nominations for Breakthrough Prizes for 2014. The rules and nomination form are made available in their official site. As per the rules, anyone can nominate a candidate online and all submissions must be completed by a third party. Nominations will be accepted through October 2, 2013. This year the foundation will award up to five prizes worth $3 million each, sponsored by Sergey Brin and Anne Wojcicki, Mark Zuckerberg and Priscilla Chan, and Yuri Milner. All prizes will be awarded for research aimed at curing deadly diseases and extending human life, with special attention to recent discoveries. One prize sponsored by Sergey Brin and Anne Wojcicki is aimed specifically at advancements in Parkinson's disease research. The 2014 prize winners will be chosen by the foundation's selection committee, comprised of prior recipients of the Breakthrough Prize in life sciences, including, Cornelia I. Bargmann, David Botstein, Lewis C. Cantley, Hans Clevers, Napoleone Ferrara, Titia de Lange, Eric S. Lander, Charles L. Sawyers, Bert Vogelstein, Robert A. Weinberg, and Shinya Yamanaka. "We all benefit from the brilliance and commitment of researchers at the frontiers of medical science. This is a chance to reward their achievements and support their future work. If you think someone deserves a Breakthrough Prize, you have the power to put them in the running," said Mr Art Levinson, Chairman of Apple Inc., Genentech, and The Breakthrough Prize in Life Sciences foundation.
    [Show full text]